Drug intelligence / Profile preview

GDA-301

Development stage: Discontinued
Lead developer: Gamida Cell
Modality: Cell Therapies
Administration: Injection

Overview

GDA-301 is an investigational, genetically modified natural killer (NK) cell therapy derived using Gamida Cell’s nicotinamide (NAM)-enabled platform, engineered with CISH gene knockout and membrane-bound interleukin-15 (mbIL-15) expression to enhance NK-cell cytotoxicity, degranulation, and proinflammatory cytokine production against hematologic malignancies and solid tumors. Preclinical data showed increased killing of K562 (CML) and RPMI (multiple myeloma) cell lines versus control NAM-NK cells. No regulatory approvals have been granted and no FDA designations are reported. The intended administration is by injection for oncology indications.

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CISH (Cytokine-inducible SH2-containing protein)

Beyond the preview

Go deeper on GDA-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDA-301.

Explore the full profile